If you have been reading about peptide acylation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
During the 2026 legislative session, Moore proposed an additional $150 million in cuts to the DDA as well as a $500,000 cap on the total amount of state funding a single person with a DDA waiver could receive in a year for their health needs. The Maryland Senate reduced these cuts to $126 million and rejected the health services cap, but retained several other cost containment measures proposed by Moore. In May 2025, Moore signed into law a bill requiring insurers to cover vaccinations recommended by the Advisory Committee on Immunization Practices as of December 2024. In September 2025, amid efforts by Health and Human Services Secretary Robert F. Kennedy Jr. to restrict access to vaccines, Maryland joined the Northeast Public Health Collaborative, a coalition of states to coordinate public health guidelines separate from the Centers for Disease Control and Prevention (CDC). During the 2026 legislative session, Moore introduced a bill that would give the Maryland Secretary of Health the ability to issue vaccine recommendations tied to guidance from major medical associations and other states. The bill passed and was signed into law by Moore in April 2026.
Dr. George D. Winter (1927–1981) was the British-born pioneer of moist wound healing. In 1962, while working at the Department of Biomechanics and Surgical Materials at the University of London, Winter published his landmark Nature paper Formation of the scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig (Nature 193:293 1962) where he demonstrated that, contrary to the conventional wisdom that wounds should be allowed to dry out and form scabs to promote healing, wounds instead healed faster if kept moist. Winter formed multiple partial thickness wounds on the backs of pigs, half left open to the air and half covered with a polymer film to keep them hydrated. The latter wounds healed faster, as measured by the migration of new epithelium on the wound bed. This work began the evolution of modern wound dressings that promote moist wound healing. George D. Winter was the first president of the European Society for Biomaterials and has an annual award named after him.
Imvescor was the parent company of the restaurant chains Scores, Pizza Delight, Mikes, Baton Rouge with a history that goes back to 1968. It was known as Pizza Delight Corporation until 2007, when the name was changed to Imvescor. As Pizza Delight Corporation, the company purchased Mikes in 2000 for $14.5 million, Quebec company Scores Rotisserie Barbecue and Ribs in 2005 for $32 million and Baton Rouge Restaurants. Headquartered in Moncton, the company was in charge of 259 restaurants across Canada (101 Pizza Delight, 91 Mikes, 39 Scores, and 28 Baton Rouge). Imvescor used to be a privately owned corporation that held the licence for the trademark and intellectual property of the four restaurants by PDM Royalties Income Fund. In 2009, the income fund and Imvescor combined their businesses into a new corporation called Imvescor Restaurant Group Inc. The four restaurant chains employed over 10,000 people. Total system sales in 2009 were $324.8 million. Imvescor is now owned by MTY Food Group, after being acquired in December 2017.
Sources: en.wikipedia.org
Because of the large energy distribution, ions with similar mass/charge ratio can have very different kinetic energies and will thus experience different deflection for the same magnetic field. In practical terms one would see that ions with the same mass/charge ratio focus at different points in space. However, in a mass-spectrometer one wants ions with the same mass/charge ratio to focus at the same point, e.g. where the detector is located. In order to overcome these limitations, commercial MC-ICP-MS are double-focusing instruments. In a double-focusing mass-spectrometer ions are focused due to kinetic energy by the ESA (electro-static-analyzer) and kinetic energy + mass/charge (momentum) in the magnetic field. Magnet and ESA are carefully chosen to match the energy focusing properties of one another and are arranged so that the direction of energy focusing is in opposite directions. To simplify, two components have an energy focus term, when arranged properly, the energy term cancels out and ions with the same mass/charge ratio focus at the same point in space. Double-focusing does not reduce the kinetic energy distribution and different kinetic energies are not filtered or homogenized. Double-focusing works for single as well as multi-collector instruments. In single collector instruments ESA and magnet can be arranged in either forward geometry (first ESA then magnet) or reversed geometry (magnet first then ESA), as only point-to-point focusing is required.
== History == Mobocertinib was studied in participants with previously treated metastatic non-small cell lung cancer with EGFR exon 20 insertions. The FDA granted the application for mobocertinib orphan drug designation.
Less common but occasional symptoms include erythrocytosis, leukocytosis, and proteinuria. The physical changes of hypersomatotropism are a result of anabolic effects of growth hormone and IGF-1; these have a gradual onset and progress slowly. The overgrowth of soft tissue and bone changes cause weight gain, broadening of the skull, prognathia inferior, and an enlarged tongue. Thickening of the oropharyngeal tissue may lead to respiratory distress and stridor. Degenerative anthropathy is caused by proliferation of chondrocytes and changes to the joint geometry. Heart murmur occurs in most feline cases, further diagnostics may reveal cardiomegaly and other heart abnormalities. Congestive heart failure can occur during later stages of the disease. A 1990 study reported 50% of cats diagnosed with hypersomatotropism had developed renal failure within 8–36 months of initial examination; however, another study from 2007 found a 12% incidence of azotaemia. Renal failure is a very common disease in elderly cats and it is controversial as to whether or not feline hypersomatotropism affects the development of renal failure. In dogs the symptoms of diabetes mellitus commonly overshadows acromegalic symptoms.
=== Chondrichthyes === The myomeres of some Chondrichthyes, specifically sharks, are W-shaped. Thus, function in Chondrichthyes is similar to that of bony fish, where myomeres contribute to propulsive force for locomotion.
Sources: en.wikipedia.org
The above reactions are balanced if Pi represents the H2PO4− ion, ADP and GDP the ADP2− and GDP2− ions, respectively, and ATP and GTP the ATP3− and GTP3− ions, respectively. The total number of ATP molecules obtained after complete oxidation of one glucose in glycolysis, citric acid cycle, and oxidative phosphorylation is estimated to be between 30 and 38.
From 15 to 20 February, the Battle of Wadi al-Batin took place inside Iraq; this was the first of two attacks by 1 Battalion 5th Cavalry of the 1st Cavalry Division. It was a feint attack, designed to make the Iraqis think that a coalition invasion would take place from the south. The Iraqis fiercely resisted, and the Americans eventually withdrew as planned back into the Wadi al-Batin. Three US soldiers were killed and nine wounded, with one M2 Bradley IFV turret destroyed, but they had taken 40 prisoners and destroyed five tanks, and successfully deceived the Iraqis. This attack led the way for the XVIII Airborne Corps to sweep around behind the 1st Cav and attack Iraqi forces to the west. On 22 February 1991, Iraq agreed to a Soviet-proposed ceasefire agreement. The agreement called for Iraq to withdraw troops to pre-invasion positions within six weeks following a total ceasefire, and called for monitoring of the ceasefire and withdrawal to be overseen by the UN Security Council. The coalition rejected the proposal, but said that retreating Iraqi forces would not be attacked, and gave 24 hours for Iraq to withdraw its forces. On 23 February, fighting resulted in the capture of 500 Iraqi soldiers. On 24 February, British and American armored forces crossed the Iraq–Kuwait border and entered Iraq in large numbers, taking hundreds of prisoners. Iraqi resistance was light, and four Americans were killed.
== Reading == Cook, T. R.; Zheng, Y.; Stang, P. J. (2013). "Metal-organic frameworks and self-assembled supramolecular coordination complexes: Comparing and contrasting the design, synthesis, and functionality of metal-organic materials". Chem. Rev. 113 (1): 734–77. doi:10.1021/cr3002824. PMC 3764682. PMID 23121121.{{cite journal}}: CS1 maint: multiple names: authors list (link) Desiraju, G. R. (2013). "Crystal engineering: From molecule to crystal". J. Am. Chem. Soc. 135 (27): 9952–67. Bibcode:2013JAChS.135.9952D. doi:10.1021/ja403264c. PMID 23750552. Seto, C. T.; Whitesides, G. M. (1993). "Molecular self-assembly through hydrogen bonding: Supramolecular aggregates based on the cyanuric acid-melamine lattice". J. Am. Chem. Soc. 115 (3): 905–916. Bibcode:1993JAChS.115..905S. doi:10.1021/ja00056a014.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.